Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 may slow disease progression and decrease the severity of symptoms
If you meet the following three criteria, you may be eligible for the study. Participate! Help us!
- Positive in COVID-19
- Age ≥ 50 years
If you have any questions, please contact the researchers by calling 634 755 945 or sending an e-mail to firstname.lastname@example.org.
Description of the Study:
- Title: Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients.
- Principal Investigators: Oriol Mitjà and Bonaventura Clotet.
- Centers of Implementation: Centers in the health region of Bages-Berguedà, Barcelona, Metropolitan South and Metropolitan North. In Catalunya Central, people who meet the requirements will be treated at CUAP Bages and in the Emergency Room of the Hospital Sant Bernabé de Berga.
- Study Population: People with 50 years of age or older who have had a positive COVID-19 result by PCR or rapid antigen test and who have symptoms not requiring hospitalization for less than 7 days.
- Study type: Double-blind, Randomized, Prospective Clinical Trial.
- Design: Randomized study, in which there will be two treatment groups that, in addition to the therapy prescribed by their medical professional for COVID-19, will receive either convalescent plasma or placebo. Assignment to one group or the other will be randomized. It is also a double-blind study in which neither the research team nor the participant will know to which group the latter belongs.
- Methods: The two treatments (convalescent plasma and placebo) will be administered by intravenous infusion of about 30-40 minutes of duration in a hospital setting. Administration will be performed on the first day of the study, after checking blood group compatibility.
Objectives of the Study:
Principal Objective: To evaluate the efficacy and safety of convalescent plasma treatment in people over 50 years of age with mild to moderate COVID-19 disease who are not hospitalized.
More about this Study:
Scientific context: Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by the SARS-CoV-2 virus. The uncontrolled spread of the SARS-CoV-2 coronavirus has generated an unprecedented health emergency that requires the urgent development of new strategies to protect the population, mainly those most at risk.
Convalescent plasma is given by persons who have passed COVID-19 and contain antibodies against the SARS-CoV-2 virus.
Plasma therapy has been used to treat many conditions and is safe. Convalescent plasma therapy could be very useful for the entire population, mainly for those who are older or have risk factors for developing complications of COVID-19.
Other Clinical Trials:
Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.
This study aims to demonstrate efficacy of Montelukast for patients with persistent COVID-19 to help them improve their quality of life.
Solidarity is an international clinical trial to evaluate the effect of a number of drugs for the treatment of COVID-19.
This study aims to determine the validity of a new method to detect COVID-19 by characterising molecules in exhaled air.
Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.
This clinical trial aims to explore the efficacy of allogeneic mesenchymal cells from umbilical cord tissue in patients with severe COVID-19 lung disease.
Can sex hormones help men survive COVID-19? This study assesses the safety and efficacy of progesterone for the treatment of COVID-19 in hospitalized men.
Open, randomized, adaptive, phase III clinical trial study to evaluate the efficacy of various pharmacological alternatives in the treatment of severe infection in COVID-19 pediatric patients.